Dyne Therapeutics, Inc. (DYN)Â
NASDAQ$10.995-0.41 (-3.60%)
Market Cap
$1.29B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
220 of 919
Rank in Industry
127 of 523
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
DYN Insider Trading Activity
DYN Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $264,304 | 1 | 1 |
Sells | $110,868,028 | 85 | 99 |
Related Transactions
| Cox John | CEO & President | 1 | $264,304 | 1 | $48,042 | $216,262 |
| Friedl-Naderer Johanna | Chief Commercial Officer | 0 | $0 | 1 | $1,733 | $-1,733 |
| Kerr Douglas | Chief Medical Officer | 0 | $0 | 1 | $15,888 | $-15,888 |
| Rhodes Jason P | director | 0 | $0 | 1 | $25,884 | $-25,884 |
| Farwell Wildon | Chief Medical Officer | 0 | $0 | 3 | $254,464 | $-254,464 |
| McNeill Jonathan | Chief Business Officer | 0 | $0 | 3 | $257,607 | $-257,607 |
| Incerti Carlo | director | 0 | $0 | 1 | $474,045 | $-474,045 |
| Beskrovnaya Oxana | Chief Scientific Officer | 0 | $0 | 11 | $1.63M | $-1.63M |
| Scalzo Richard William | SVP, Head of Finance & Admin. | 0 | $0 | 12 | $4.61M | $-4.61M |
| HIGH SUSANNA GATTI | Chief Operating Officer | 0 | $0 | 9 | $6.01M | $-6.01M |
| Kersten Dirk | director | 0 | $0 | 42 | $97.54M | $-97.54M |
About Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Insider Activity of Dyne Therapeutics, Inc.
Over the last 12 months, insiders at Dyne Therapeutics, Inc. have bought $264,304 and sold $110.87M worth of Dyne Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Dyne Therapeutics, Inc. have bought $22.9M and sold $59.16M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Cox John (CEO & President) — $264,304.
The last purchase of 8,000 shares for transaction amount of $264,304 was made by Cox John (CEO & President) on 2024‑09‑04.
List of Insider Buy and Sell Transactions, Dyne Therapeutics, Inc.
| 2025-03-13 | Sale | Friedl-Naderer Johanna | Chief Commercial Officer | 143 0.0001% | $12.12 | $1,733 | +3.41% | |
| 2025-03-11 | Sale | Beskrovnaya Oxana | Chief Scientific Officer | 2,153 0.0018% | $11.38 | $24,501 | +2.12% | |
| 2025-03-11 | Sale | Scalzo Richard William | SVP, Head of Finance & Admin. | 1,343 0.0011% | $11.38 | $15,283 | +2.12% | |
| 2025-03-05 | Sale | Beskrovnaya Oxana | Chief Scientific Officer | 1,094 0.0009% | $11.83 | $12,942 | +0.55% | |
| 2025-03-05 | Sale | Cox John | CEO & President | 4,061 0.0035% | $11.83 | $48,042 | +0.55% | |
| 2025-03-05 | Sale | Scalzo Richard William | SVP, Head of Finance & Admin. | 917 0.0008% | $11.83 | $10,848 | +0.55% | |
| 2025-03-05 | Sale | Kerr Douglas | Chief Medical Officer | 1,343 0.0011% | $11.83 | $15,888 | +0.55% | |
| 2025-02-18 | Sale | Beskrovnaya Oxana | Chief Scientific Officer | 2,598 0.0026% | $13.95 | $36,242 | -12.28% | |
| 2025-02-18 | Sale | Scalzo Richard William | SVP, Head of Finance & Admin. | 2,488 0.0025% | $13.95 | $34,708 | -12.28% | |
| 2024-12-11 | Sale | Beskrovnaya Oxana | Chief Scientific Officer | 2,334 0.0023% | $28.12 | $65,632 | -48.63% | |
| 2024-12-11 | Sale | Scalzo Richard William | SVP, Head of Finance & Admin. | 1,455 0.0015% | $28.12 | $40,915 | -48.63% | |
| 2024-12-09 | Sale | Kersten Dirk | director | 34,437 0.0341% | $29.18 | $1M | -50.78% | |
| 2024-12-06 | Sale | Kersten Dirk | director | 101,675 0.0994% | $29.34 | $2.98M | -52.14% | |
| 2024-12-05 | Sale | Kersten Dirk | director | 3,806 0.0039% | $29.05 | $110,564 | -49.08% | |
| 2024-12-04 | Sale | Kersten Dirk | director | 135,039 0.133% | $29.39 | $3.97M | -52.01% | |
| 2024-12-03 | Sale | Kersten Dirk | director | 29,732 0.0299% | $29.05 | $863,715 | -49.84% | |
| 2024-12-02 | Sale | Kersten Dirk | director | 81,201 0.0802% | $29.67 | $2.41M | -51.72% | |
| 2024-11-18 | Sale | Beskrovnaya Oxana | Chief Scientific Officer | 2,856 0.0026% | $28.20 | $80,539 | -49.66% | |
| 2024-11-18 | Sale | Scalzo Richard William | SVP, Head of Finance & Admin. | 2,735 0.0025% | $28.20 | $77,127 | -49.66% | |
| 2024-11-18 | Sale | Incerti Carlo | director | 16,500 0.0152% | $28.73 | $474,045 | -49.66% |
Total: 375
*Gray background shows transactions not older than one year
Insider Historical Profitability
1.83%
| Kersten Dirk | director | 5400545 4.7741% | $61.57M | 3 | 42 | +56.53% |
| Beskrovnaya Oxana | Chief Scientific Officer | 195840 0.1731% | $2.23M | 0 | 24 | |
| Cox John | CEO & President | 146239 0.1293% | $1.67M | 1 | 1 | |
| Farwell Wildon | Chief Medical Officer | 143222 0.1266% | $1.63M | 0 | 16 | |
| McNeill Jonathan | Chief Business Officer | 132106 0.1168% | $1.51M | 0 | 25 | |
| HIGH SUSANNA GATTI | Chief Operating Officer | 131636 0.1164% | $1.5M | 0 | 21 | |
| Scalzo Richard William | SVP, Head of Finance & Admin. | 122330 0.1081% | $1.39M | 0 | 32 | |
| Friedl-Naderer Johanna | Chief Commercial Officer | 96057 0.0849% | $1.1M | 0 | 1 | |
| Kerr Douglas | Chief Medical Officer | 94157 0.0832% | $1.07M | 0 | 1 | |
| Rhodes Jason P | director | 15962 0.0141% | $181,966.80 | 1 | 11 | <0.0001% |
| Incerti Carlo | director | 0 0% | $0 | 0 | 1 | |
| Litespeed Management, L.L.C. | 10 percent owner | 28507291 25.2007% | $324.98M | 19 | 0 | |
| ECP ControlCo, LLC | 10 percent owner | 14291152 12.6335% | $162.92M | 0 | 1 | |
| FRANKLIN RESOURCES INC | 10 percent owner | 8927023 7.8916% | $101.77M | 0 | 110 | |
| VV Manager II, LLC | 10 percent owner | 2880125 2.5461% | $32.83M | 1 | 0 | <0.0001% |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 2805045 2.4797% | $31.98M | 1 | 0 | <0.0001% |
| Logos Global Management LP | 10 percent owner | 1504392 1.3299% | $17.15M | 1 | 0 | <0.0001% |
| HURWITZ EDWARD | 1326313 1.1725% | $15.12M | 2 | 0 | ||
| Atlas Venture Opportunity Fund II, L.P. | director | 934581 0.8262% | $10.65M | 1 | 0 | <0.0001% |
| Atlas Venture Fund XI, L.P. | 10 percent owner | 864487 0.7642% | $9.86M | 0 | 9 | |
| Atlas Venture Opportunity Fund I, L.P. | 10 percent owner | 847388 0.7491% | $9.66M | 0 | 1 | |
| FLEXON ROBERT C | President and CEO | 720506 0.6369% | $8.21M | 8 | 0 | |
| Brumm Joshua T | CEO & President | 537998 0.4756% | $6.13M | 0 | 19 | |
| Lubner David Charles | director | 177872 0.1572% | $2.03M | 1 | 0 | |
| Freeland Clint | Exec. VP and CFO | 71894 0.0636% | $819,591.60 | 3 | 0 | |
| NICHOLS HOLLI | EVP and CFO | 64549 0.0571% | $735,858.60 | 0 | 1 | |
| Callaway Catherine B. | Exec VP and General Counsel | 63042 0.0557% | $718,678.80 | 1 | 0 | |
| Wood Patrick III | director | 45023 0.0398% | $513,262.20 | 3 | 0 | |
| Stehman-Breen Catherine | director | 35574 0.0314% | $405,543.60 | 1 | 0 | |
| Klein Lawrence Otto | director | 35574 0.0314% | $405,543.60 | 1 | 0 | |
| HAMMICK PATRICIA A | director | 25000 0.0221% | $285,000.00 | 3 | 0 | |
| Stein Jeffrey Scott | director | 15489 0.0137% | $176,574.60 | 1 | 0 | |
| GRIJALVA VICTOR | director | 15000 0.0133% | $171,000.00 | 1 | 0 | |
| TRUBECK WILLIAM L | director | 11000 0.0097% | $125,400.00 | 2 | 0 | |
| ELWARD THOMAS W | director | 5000 0.0044% | $57,000.00 | 1 | 0 | |
| Kuersteiner Richard Lee | director | 2500 0.0022% | $28,500.00 | 1 | 0 | |
| Ackermann Hilary E. | director | 1000 0.0009% | $11,400.00 | 1 | 0 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$8,217,280 | 112 | 46.33% | $1.22B | |
$831,902,292 | 108 | 9.34% | $1.58B | |
$20,297,544 | 73 | 103.06% | $1.69B | |
$54,590,806 | 65 | 21.84% | $1.2B | |
$1,101,324,300 | 58 | 37.37% | $1.24B | |
$100,002,191 | 42 | 21.48% | $1.33B | |
$148,770,544 | 34 | 80.63% | $1.71B | |
$309,951,506 | 30 | 32.56% | $1.17B | |
$1,295,059 | 29 | 102.78% | $1.34B | |
$7,598,498 | 27 | 34.68% | $1.16B | |
$1,272,896 | 16 | 24.56% | $1.19B | |
$154,554,190 | 14 | 29.60% | $1.76B | |
$43,198,628 | 12 | -0.10% | $1.21B | |
$45,445,266 | 9 | -24.96% | $1.58B | |
$107,703,099 | 7 | 29.71% | $1.45B | |
Dyne Therapeutics, Inc. (DYN) | $91,325,021 | 6 | 1.83% | $1.29B |
$8,503,480 | 3 | 132.88% | $1.28B | |
$142,493,653 | 3 | 4.30% | $1.68B | |
$5,000,000 | 1 | -22.84% | $1.25B |
DYN Institutional Investors: Active Positions
| Increased Positions | 108 | +47.37% | 10M | +8.86% |
| Decreased Positions | 98 | -42.98% | 10M | -8.99% |
| New Positions | 39 | New | 4M | New |
| Sold Out Positions | 34 | Sold Out | 1M | Sold Out |
| Total Postitions | 238 | +4.39% | 112M | -0.13% |
DYN Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Atlas Venture Life Science Advisors, Llc | $96,874.00 | 7.1% | 8.02M | -782 | <0.01% | 2024-12-31 |
| Fmr Llc | $96,603.00 | 7.08% | 8M | -1M | -11.41% | 2024-12-31 |
| Blackrock, Inc. | $96,029.00 | 7.04% | 7.95M | +155,288 | +1.99% | 2024-12-31 |
| Janus Henderson Group Plc | $89,142.00 | 6.53% | 7.38M | +566,146 | +8.31% | 2024-12-31 |
| Vanguard Group Inc | $80,983.00 | 5.93% | 6.7M | -160,211 | -2.33% | 2024-12-31 |
| Ra Capital Management, L.P. | $77,084.00 | 5.65% | 6.38M | 0 | 0% | 2024-12-31 |
| Fcpm Iii Services B.V. | $65,991.00 | 4.83% | 5.46M | -491,223 | -8.25% | 2024-12-31 |
| Rtw Investments, Lp | $63,041.00 | 4.62% | 5.22M | -2M | -23.46% | 2024-12-31 |
| State Street Corp | $44,906.00 | 3.29% | 3.72M | +75,524 | +2.07% | 2024-12-31 |
| Citadel Advisors Llc | $34,568.00 | 2.53% | 2.86M | -77,759 | -2.65% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.